Selectivity of Probes for PET Imaging of Dopamine D3 Receptors

Overview

Journal Neurosci Lett

Specialty Neurology

Date 2018 Mar 9

PMID 29518538

Citations 15

Authors

Robert K Doot

Jacob G Dubroff

Kyle J Labban

Robert H Mach

Affiliations

Soon will be listed here.

Abstract

Dopamine D3 receptors have key roles in behavioral reward, addiction, Parkinson's disease, and schizophrenia, and there is interest in studying their role in these disorders using PET. However, current PET radiotracers for studying D3 receptors in humans all bind to both D2 and D3 due to similarities between the two receptors. Selective D2 and D3 radioligands would aid investigation of the differences between D2 and D3 circuitry in the central nervous system. While there are currently in vitro measures of ligand D3/D2 selectivity, there is a need for an in vivo PET measure of D3/D2 selectivity. This review discusses current PET imaging of dopamine D2/D3 receptors and proposes methodology for quantitating in vivo selectivity of probes for PET imaging of dopamine D3 receptors.

Citing Articles

Intra-striatal dopaminergic inter-subject covariance in social drinkers and non-treatment-seeking alcohol use disorder participants.

Chumin E, Dzemidzic M, Yoder K Addict Biol. 2024; 29(11):e70008.

PMID: 39576234 PMC: 11583815. DOI: 10.1111/adb.70008.

characterization of [I]HY-3-24, a selective ligand for the dopamine D3 receptor.

Lee J, Kim H, Martorano P, Riad A, Taylor M, Luedtke R Front Neurosci. 2024; 18:1380009.

PMID: 38655111 PMC: 11036874. DOI: 10.3389/fnins.2024.1380009.

Third-Generation Antipsychotics and Lurasidone in the Treatment of Substance-Induced Psychoses: A Narrative Review.

Ricci V, de Berardis D, Maina G Healthcare (Basel). 2024; 12(3).

PMID: 38338224 PMC: 10855531. DOI: 10.3390/healthcare12030339.

Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D and D receptors.

Tian G, Hsieh C, Taylor M, Lee J, Riad A, Luedtke R Eur J Med Chem. 2023; 261:115751.

PMID: 37688938 PMC: 10841072. DOI: 10.1016/j.ejmech.2023.115751.

Insights into the Involvement and Therapeutic Target Potential of the Dopamine System in the Posttraumatic Stress Disorder.

Liu M, Tian X, Fang T, Wu N, Li H, Li J Mol Neurobiol. 2023; 60(7):3708-3723.

PMID: 36933147 DOI: 10.1007/s12035-023-03312-z.

References

Mach R, Tu Z, Xu J, Li S, Jones L, Taylor M . Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study. Synapse. 2010; 65(8):724-32. PMC: 3107898. DOI: 10.1002/syn.20891. View

Alakurtti K, Aalto S, Johansson J, Nagren K, Tuokkola T, Oikonen V . Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography. J Cereb Blood Flow Metab. 2010; 31(1):155-65. PMC: 3049480. DOI: 10.1038/jcbfm.2010.64. View

Shotbolt P, Tziortzi A, Searle G, Colasanti A, Van der Aart J, Abanades S . Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab. 2011; 32(1):127-36. PMC: 3323295. DOI: 10.1038/jcbfm.2011.115. View

Black K, Piccirillo M, Koller J, Hseih T, Wang L, Mintun M . Levodopa effects on [ (11)C]raclopride binding in the resting human brain. F1000Res. 2015; 4:23. PMC: 4490799. DOI: 10.12688/f1000research.5672.1. View

Seeman P, Ko F, Willeit M, McCormick P, Ginovart N . Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors. Synapse. 2005; 58(2):122-8. DOI: 10.1002/syn.20193. View

Tziortzi A, Searle G, Tzimopoulou S, Salinas C, Beaver J, Jenkinson M . Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage. 2010; 54(1):264-77. DOI: 10.1016/j.neuroimage.2010.06.044. View

McCormick P, Kapur S, Seeman P, Wilson A . Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nucl Med Biol. 2007; 35(1):11-7. DOI: 10.1016/j.nucmedbio.2007.08.005. View

Matuskey D, Worhunksy P, Correa E, Pittman B, Gallezot J, Nabulsi N . Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers. Neuroimage. 2016; 130:241-247. PMC: 4808424. DOI: 10.1016/j.neuroimage.2016.02.002. View

Newman A, Grundt P, Nader M . Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem. 2005; 48(11):3663-79. DOI: 10.1021/jm040190e. View

10.

Payer D, Behzadi A, Kish S, Houle S, Wilson A, Rusjan P . Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO. Neuropsychopharmacology. 2013; 39(2):311-8. PMC: 3870773. DOI: 10.1038/npp.2013.192. View

11.

Kegeles L, Slifstein M, Xu X, Urban N, Thompson J, Moadel T . Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry. 2010; 68(7):634-41. PMC: 2952433. DOI: 10.1016/j.biopsych.2010.05.027. View

12.

Kumar R, Riddle L, Griffin S, Chu W, Vangveravong S, Neisewander J . Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology. 2009; 56(6-7):956-69. PMC: 4106465. DOI: 10.1016/j.neuropharm.2009.01.019. View

13.

Narendran R, Mason N, Chen C, Himes M, Keating P, May M . Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release. Synapse. 2011; 65(10):991-7. PMC: 3135684. DOI: 10.1002/syn.20926. View

14.

Sokoloff P, Giros B, Martres M, Bouthenet M, Schwartz J . Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990; 347(6289):146-51. DOI: 10.1038/347146a0. View

15.

Gurevich E, Joyce J . Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology. 1999; 20(1):60-80. DOI: 10.1016/S0893-133X(98)00066-9. View

16.

Worhunsky P, Matuskey D, Gallezot J, Gaiser E, Nabulsi N, Angarita G . Regional and source-based patterns of [C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D and D receptor availability in cocaine-use disorder. Neuroimage. 2017; 148:343-351. PMC: 5344702. DOI: 10.1016/j.neuroimage.2017.01.045. View

17.

Christian B, Narayanan T, Shi B, Mukherjee J . Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [(18)F]fallypride in nonhuman primates. Synapse. 2000; 38(1):71-9. DOI: 10.1002/1098-2396(200010)38:1<71::AID-SYN8>3.0.CO;2-2. View

18.

Carlsson J, Coleman R, Setola V, Irwin J, Fan H, Schlessinger A . Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol. 2011; 7(11):769-78. PMC: 3197762. DOI: 10.1038/nchembio.662. View

19.

Sun J, Xu J, Cairns N, Perlmutter J, Mach R . Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. PLoS One. 2012; 7(11):e49483. PMC: 3504049. DOI: 10.1371/journal.pone.0049483. View

20.

Keck T, John W, Czoty P, Nader M, Newman A . Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis. J Med Chem. 2015; 58(14):5361-80. PMC: 4516313. DOI: 10.1021/jm501512b. View